Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Renate M Hoogeveen; Matthias Nahrendorf; Niels P Riksen; Mihai G Netea; Menno P J de Winther; Esther Lutgens; Børge G Nordestgaard; Michel Neidhart; Erik S G Stroes; Alberico L Catapano; Siroon Bekkering

doi:10.1093/eurheartj/ehx581

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Renate M Hoogeveen, Matthias Nahrendorf, Niels P Riksen, Mihai G Netea, Menno P J de Winther, Esther Lutgens, Børge G Nordestgaard, Michel Neidhart, Erik S G Stroes, Alberico L Catapano, Siroon Bekkering

Department of Clinical Medicine

30 Citations (Scopus)

30 Downloads (Pure)

Abstract

A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

Original language	English
Journal	European Heart Journal
Volume	39
Issue number	38
Pages (from-to)	3521-3527
Number of pages	7
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehx581
Publication status	Published - 7 Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurheartj/ehx581Licence: CC BY-NC

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseasesFinal published version, 497 KBLicence: CC BY-NC

Cite this

Hoogeveen, R. M., Nahrendorf, M., Riksen, N. P., Netea, M. G., de Winther, M. P. J., Lutgens, E., Nordestgaard, B. G., Neidhart, M., Stroes, E. S. G., Catapano, A. L., & Bekkering, S. (2018). Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 39(38), 3521-3527. https://doi.org/10.1093/eurheartj/ehx581

Hoogeveen, RM, Nahrendorf, M, Riksen, NP, Netea, MG, de Winther, MPJ, Lutgens, E, Nordestgaard, BG, Neidhart, M, Stroes, ESG, Catapano, AL & Bekkering, S 2018, 'Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases', European Heart Journal, vol. 39, no. 38, pp. 3521-3527. https://doi.org/10.1093/eurheartj/ehx581

@article{5187c41e0b8948b78bac65605526bae5,

title = "Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases",

abstract = "A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.",

author = "Hoogeveen, {Renate M} and Matthias Nahrendorf and Riksen, {Niels P} and Netea, {Mihai G} and {de Winther}, {Menno P J} and Esther Lutgens and Nordestgaard, {B{\o}rge G} and Michel Neidhart and Stroes, {Erik S G} and Catapano, {Alberico L} and Siroon Bekkering",

year = "2018",

month = oct,

day = "7",

doi = "10.1093/eurheartj/ehx581",

language = "English",

volume = "39",

pages = "3521--3527",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "38",

}

TY - JOUR

T1 - Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

AU - Hoogeveen, Renate M

AU - Nahrendorf, Matthias

AU - Riksen, Niels P

AU - Netea, Mihai G

AU - de Winther, Menno P J

AU - Lutgens, Esther

AU - Nordestgaard, Børge G

AU - Neidhart, Michel

AU - Stroes, Erik S G

AU - Catapano, Alberico L

AU - Bekkering, Siroon

PY - 2018/10/7

Y1 - 2018/10/7

N2 - A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

AB - A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

U2 - 10.1093/eurheartj/ehx581

DO - 10.1093/eurheartj/ehx581

M3 - Review

C2 - 29069365

SN - 0195-668X

VL - 39

SP - 3521

EP - 3527

JO - European Heart Journal

JF - European Heart Journal

IS - 38

ER -

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this